Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7310959 | 0.73 | SSTR4 (0.42) | RENSSTR4 | |
| SCHEMBL715379 | 0.73 | GABRA5 (0.47) | — | |
| SCHEMBL27515664 | 0.73 | SLC6A1 (0.44) | RENSSTR4 | |
| SCHEMBL3559589 | 0.73 | SSTR4 (0.38) | RENSSTR4 | |
| SCHEMBL11524373 | 0.73 | SLC6A1 (0.37) | — | |
| SCHEMBL23230712 | 0.72 | SSTR4 (0.44) | RENSSTR4 | |
| SCHEMBL946968 | 0.72 | SLC6A1 (0.33) | — | |
| SCHEMBL294851 | 0.72 | SSTR4 (0.41) | RENSSTR4 | |
| SCHEMBL3364696 | 0.72 | SSTR4 (0.41) | RENSSTR4 | |
| SCHEMBL2688364 | 0.72 | SSTR4 (0.41) | RENSSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403847-B1 | TRIAZINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-8785628-B2 | Triazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2014-07-22 | — | — | US | disclosed |
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | UCB PHARMA, S.A. (BE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053167-A1 | Triazine Derivatives as Kinase Inhibitors | MAP3K15, PI4KA, MAP3K20 | REN 928/4885SSTR4 3133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.